C.J. George Chang, DVM, MS, PhD, DABT
Company:  US Food and Drug Administration
Email: gchang2004@yahoo.com
Phone: US +1  2407938425 Call
Website: www.fda.gov

Dr. C.J. George Chang is a native from Taiwan, ROC, and is a veterinarian, veterinary pathologist & pharmacologist, and toxicologist by training. He is a board-certified toxicologist, auditor, and regulatory affairs and project management specialist. Currently, Dr. Chang serves as a regulatory scientist at the Division of Animal Feeds, Office of Surveillance & Compliance, Center for Veterinary Medicine, US FDA and is responsible for regulatory and toxicology reviews of candidate feed ingredients and safety evaluation of marketed pet food and animal feeds.

Before becoming a Federal officer, Dr. Chang had been managing team operations for preclinical & clinical drug development in pharmaceutical industry, assisting in building a world-known toxicogenomics safety prediction database, and directing contract research projects and programs. Dr. Chang earned his veterinary medicine degree from National Taiwan University, Taiwan, ROC; his first MS degree in Vet. pathology from University of Minnesota; and his second MS and PhD degrees in Vet. physiology/pharmacology from The Ohio State University. He conducted his post-doc research on the molecular dosimetry, and investigated the subacute and subchronic effects of and chemotherapeutical prevention/intervention potential of candidate compounds for the most toxic tobacco-specific nitrosamine, NNK, at a Wake Forest U/RJR Tobacco joint postdoctoral research program, NC.

Currently, Dr. Chang serves on the Boards of Directors of a few Metropolitan Washington-DC chapters for the following national or international organizations: the Chinese American Professional Association, Monte-Jade Science and Technology Association, Society of Quality Assurance, and American Society of Quality (chair its Biomed/Biotech SIG).  Dr. Chang’s career goals reside in assessing the functionality, efficacy, and safety of biomedical candidate products; facilitating quality collaboration among scientific communities; setting critical scientific regulatory standards and policies; and assisting persistent surveillance and timely enforcement on adulterated/misbranded biomedical products to protect the health of the general public.